A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer

Published:2018-03 Issue:3 Volume:1864 Page:735-745
ISSN:0925-4439
Container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Author:

Ojo Diane,Wu Ying,Bane Anita,Tang Damu

Funder

Teresa Cascioli Charitable Foundation Research Award

Canadian Cancer Society

Publisher

Elsevier BV

Subject

Molecular Biology,Molecular Medicine

Reference49 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int. J. Cancer,2015

2. Factors promoting tamoxifen resistance in breast cancer via stimulating breast cancer stem cell expansion;Ojo;Curr. Med. Chem.,2015

3. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer;Clark;J. Clin. Oncol.,1984

4. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer;Harvey;J. Clin. Oncol.,1999

5. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer;Eeckhoute;Genes Dev.,2006

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges;Life Sciences;2024-07

2. Construction of a breast cancer predictive nomogram based on diverse cell death methods and reveal tumor microenvironment characterization;2024-05-14

3. Exploring the anticancer potential of thiadiazole derivatives of substituted thiosemicarbazones formed via copper‐mediated cyclization;Applied Organometallic Chemistry;2023-06-27

4. Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer;Technology in Cancer Research & Treatment;2022-01

5. SIPL1, Regulated by MAZ, Promotes Tumor Progression and Predicts Poor Survival in Human Triple-Negative Breast Cancer;Frontiers in Oncology;2021-12-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3